Is rosmarinic acid underestimated as an experimental cardiovascular drug?

Acta Cir Bras. 2013:28 Suppl 1:83-7. doi: 10.1590/s0102-86502013001300016.

Abstract

Purpose: The rationale of the present review is to analize the activity of Rosmarinus officinalis in the the cardiovascular system

Methods: A MEDLINE database search (from January 1970 to December 2011) using only rosmarinic acid as searched term.

Results: The references search revealed 509 references about rosmarinic acid in 40 years (the first reference is from 1970). There is a powerful prevalence of antioxidant and cancer studies. Other diseases are few cited, as inflammation, brain (Alzheimer and Parkinson disease) and, memory; allergy; diabetes; atherosclerosis, and; hypertension. It is necessary to consider the complete absence of studies on coronary artery disease, myocardial ischemia, heart failure or ischemia/reperfusion injury.

Conclusion: Rosmarinic acid is underestimated as an experimental cardiovascular drug and deserves more attention.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Cardiovascular Agents / pharmacology
  • Cardiovascular Agents / therapeutic use*
  • Cardiovascular Diseases / drug therapy*
  • Cinnamates / pharmacology
  • Cinnamates / therapeutic use*
  • Depsides / pharmacology
  • Depsides / therapeutic use*
  • Humans
  • Rosmarinic Acid

Substances

  • Cardiovascular Agents
  • Cinnamates
  • Depsides